Effect of bifendate on the pharmacokinetics of talinolol in healthy subjects.
To evaluate the effect of bifendate on the pharmacokinetics of talinolol, 16 unrelated male healthy subjects were selected for this study. After repeated oral administration of placebo or bifendate (three times daily for 14 days), the plasma concentration of talinolol was measured by high-performance liquid chromatography-electrospray mass spectrometry. This study was carried out in a randomized, single-blinded, placebo-controlled, crossover manner. After the treatment of bifendate, the area under the curve (AUC(0-infinity)) was decreased significantly by 11.2% (90% confidence interval (CI), 7.3-12.4%; p = 0.001), and the Cmax value of talinolol was decreased by approximately 9.7% (90% CI, 5.5-11.4%; p = 0.001). The oral clearance of talinolol was increased significantly by 13.1% (90% CI, 8.0-14.4%; p = 0.001). The results suggest that the treatment of bifendate can decrease the plasma concentration of talinolol in healthy subjects.
Zeng
Y
Y
Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, P. R. China.
He
F-Y
FY
He
Y-J
YJ
Dai
L-L
LL
Fan
L
L
Zhou
H-H
HH
D000284:Administration, Oral; D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics*; D000328:Adult; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D018592:Cross-Over Studies; D004347:Drug Interactions; D006801:Humans; D008297:Male; D011412:Propanolamines / Q000493:pharmacokinetics*; D016037:Single-Blind Method; D055815:Young Adult
D000319:Adrenergic beta-Antagonists; D001713:Biphenyl Compounds; D011412:Propanolamines; C465548:bifendate; C011550:talinolol